Compare Corsair Gaming Inc (CRSR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs TG Therapeutics Inc — how do they compare? Corsair Gaming Inc trades at $13.64 (market cap $1.42B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 5.7× Corsair Gaming Inc's market cap, and TG Therapeutics Inc is more actively traded (1,735,121 versus 1,160,938). Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and TG Therapeutics Inc for 16 Days on average.
| CRSR | TGTX | |
|---|---|---|
Market Cap | $1.42B | $8.16B |
Volume | 1,160,938 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $14.35 | $59.06 |
52-Week Low | $4.58 | $26.94 |
Typical Hold Time | 25 Days | 16 Days |
Enterprise Value | $1.41B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.505, down 0.63% on the day, with a bullish technical signal and recent earnings beats driving positive momentum. The stock shows improving fundamentals with a projected net income margin of 2.53% for 2026, though current valuation metrics like a P/E of 42.23 appear elevated. Recent product launches and strategic acquisitions highlight growth initiatives in the gaming and creator segments.
The outlook is cautiously optimistic, supported by analyst buy ratings and strong cash flow projections for 2026. Key risks include competitive pressures and reliance on consumer discretionary spending, but institutional interest and earnings outperformance provide a foundation for potential upside if execution continues.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
